A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen’s Shares in Lotus and Adalvo in a US$475m Deal
Retrieved on:
Friday, November 26, 2021
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, Patient, Senior, Nutrition, CEO, Peptide, CVS, Time, EBITDA, CAGR, Partnership, TWSE, Brazil, Central nervous system, Founder, PTT, Goal, PTT Public Company Limited, Research, List of life sciences, Tablet, Board, US FDA, SET, Health technology, Innovation, CVC Capital Partners, Stock Exchange of Thailand, Medication, Growth, GX, CNS, Fine chemical, Management, Pharmaceutical industry, Renewable energy, Aztiq, Innobic, Lotus, Adalvo, AZTIQ, INNOBIC, LOTUS, ADALVO
Key shareholders in Alvogen include CVC Capital Partners (CVC) and Temasek Holdings of Singapore (Temasek), as well as Aztiq.
Key Points:
- Key shareholders in Alvogen include CVC Capital Partners (CVC) and Temasek Holdings of Singapore (Temasek), as well as Aztiq.
- Rbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq, will continue to serve as Chairman of the board of Lotus and Adalvo.
- Rbert Wessman, Chairman and CEO of Alvogen/ Founder of Aztiq, commented: I am very proud to have witnessed the maturation of both Lotus and Adalvo.
- In April of 2021, Innobic invested approximately US$50 million into Lotus by acquiring newly-issued shares via a private placement.